The purpose of this study is to examine whether combination of brexpiprazole and SSRI fluoxetine could improve depression-like behaviors and alterations in the brain-derived neurotrophic factor (BDNF) - TrkB signaling and dendritic spine density in the selected brain regions after a single LPS administration. The gene discussed is BDNF; the disease is major depressive disorder.